葛蘭素史克胃藥致癌案首宗訴訟達成和解
英國藥廠葛蘭素史克(GSK)與一名美國公民達成和解,後者指控公司停產的抑制胃酸藥物Zantac致癌。葛蘭素史克表示,雙方達成保密和解,審訊將被撤回,公司將可避免首宗此類訴訟進入審訊階段。
Zantac於1983年獲得批准,但在2019年一些藥廠停止銷售Zantac,因該藥其中一種成份雷尼替丁(ranitidine)在一段時間後會分解出一種名為NDMA的化學物質,而大量累積NDMA後會致癌。美國食品與藥物管理局(FDA)於2020年從市場上撤回所有品牌的Zantac及其仿製藥。
葛蘭素史克表示,今次和解不代表公司會承認任何責任,強調公司繼續根據事實及科學證據來進行積極抗辯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.